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Abstract
Paracoccidioidomycosis (PCM), caused by Paracoccidioides brasiliensis, is the most prevalent invasive fungal disease in South
America. Systemic mycoses are the 10th most common cause of death among infectious diseases in Brazil and PCM is
responsible for more than 50% of deaths due to fungal infections. PCM is typically treated with sulfonamides, amphotericin
B or azoles, although complete eradication of the fungus may not occur and relapsing disease is frequently reported. A 15-
mer peptide from the major diagnostic antigen gp43, named P10, can induce a strong T-CD4+ helper-1 immune response in
mice. The TEPITOPE algorithm and experimental data have confirmed that most HLA-DR molecules can present P10, which
suggests that P10 is a candidate antigen for a PCM vaccine. In the current work, the therapeutic efficacy of plasmid
immunization with P10 and/or IL-12 inserts was tested in murine models of PCM. When given prior to or after infection with
P. brasiliensis virulent Pb 18 isolate, plasmid-vaccination with P10 and/or IL-12 inserts successfully reduced the fungal
burden in lungs of infected mice. In fact, intramuscular administration of a combination of plasmids expressing P10 and IL-
12 given weekly for one month, followed by single injections every month for 3 months restored normal lung architecture
and eradicated the fungus in mice that were infected one month prior to treatment. The data indicate that immunization
with these plasmids is a powerful procedure for prevention and treatment of experimental PCM, with the perspective of
being also effective in human patients.
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Introduction
Paracoccidioides brasiliensis is a thermally dimorphic fungus that
causes a systemic granulomatous disease known as paracoccidioi-
domycosis (PCM). PCM is widespread in Latin America, mainly
affecting rural workers, and its incidence has increased in recently
deforested areas associated with soil churning [1]. Acquisition of P.
brasiliensis may arise from inhalation of aerosolized conidia.
Recently we reviewed the death rates by systemic mycoses in
Brazil [2]. PCM was the principal cause of death identified for
3,583 patients in the 1996–2006 decade and representing
51.2% of total deaths due to systemic mycoses. It ranks as the
10th most common cause of death among infectious diseases in
Brazil [2].
There are distinct forms of PCM. The acute and sub-acute
forms affect both genders with primary involvement of the
reticuloendothelial/lymphatic system. The chronic form affects
mainly adult males and predominantly causes pulmonary and/or
mucocutaneous disease [3]. Antifungal chemotherapy is required
for treatment, though treatment may not assure complete
eradication of the fungus, with frequent relapses. Treatment with
itraconazole usually takes 6–9 months in the low and 12–18
months in the moderately severe cases. Frequently, a combination
of trimethoprim and sulfamethoxazole (TMP/SMZ) is used, held
for 12 months in the low severity forms and 18–24 months in the
moderately severe forms. Patients with severe PCM forms require
endovenous treatment with anfothericin B or the TMP/SMZ
association for long periods, monitored by clinical, radiological
and serological tests [4].
The 43 kDa glycoprotein was characterized as the major
diagnostic antigen of P. brasiliensis [5,6,7]. Immunization with gp43
elicited delayed hypersensitivity reactions in guinea pigs [8] and
humans [9], implying the presence of T-CD4+ reacting epitopes.
Based on the sequence of gp43 [6], which encodes a polypeptide of
416 amino acids with a single high mannose N-glycosylated chain
[10], the T-cell epitope was mapped to a 15-mer peptide called
P10 [11]. The hexapeptide HTLAIR comprises the essential core
of P10 that induces proliferation of lymph node cells from mice
sensitized to gp43 or infected with P. brasiliensis [11]. Type 1-T
helper lymphocytes producing IL-2 and IFN-c are induced by P10
[11,12,13]. Intratracheally infected mice previously immunized
with P10 in the presence of complete Freund’s adjuvant (CFA) had
.200-fold reduction of lung P. brasiliensis colony-forming units
(CFUs). In many cases the immunization rendered preserved lung
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architecture with few or no yeasts, whereas the infected,
unimmunized mice displayed dense pulmonary inflammation
characterized by epithelioid granulomas with numerous yeast cells
[11,12].
The immunoprotection by P10 depends on the IFN-c-
producing Th-1 response since mice deficient in IFN-c, IFN-c-R
or IRF-1, but not IFN-a-R/IFN-b-R, were not protected by P10
immunization [12] The essential role of IFN-c in organizing
granulomas that contain P. brasiliensis yeasts has also been
recognized by other investigators [13,14,15].
Several experimental avenues have been pursued to validate
P10 as a vaccine candidate. These studies have included: a) the
presentation of P10 by MHC molecules from different murine
haplotypes [11]; b) its conservation in nature, confirmed by
examining gp43 molecules from different isolates [16]; c) its
immunogenicity and effective immunoprotection in formulations
that do not require complete Freund’s adjuvant [17]; d) its
presentation by most human HLA-DR molecules as well as that of
neighbor peptides to P10, based on the sequence of gp43 [18]; and
e) the effectiveness of P10 as an adjuvant to chemotherapy in
normal [19] and anergic [20] mice challenged intratracheally with
virulent P. brasiliensis.
The immunoprotective properties of P10 emulsified in Freund’s
adjuvant have been well documented in an established murine
model of PCM [11]. Since CFA is not allowed in human vaccines
and a tetramer of truncated P10 although immunogenic, involves
laborious chemical methods [17], we have explored alternative
approaches for P10 delivery. In the present work we have
investigated the effectiveness of plasmid immunization with P10
and/or IL-12 inserts given prior to or after challenge with a
virulent Pb18 isolate of P. brasiliensis using a murine pulmonary
PCM disease model. Our results demonstrate that plasmid
immunization with P10 with or without IL-12 inserts is highly
therapeutic in mice intratracheally infected with this fungus. Most
importantly, immunization was effective either prior to, or after
infection suggesting that these plasmids are candidates for use in
human PCM.
Materials and Methods
Plasmid constructions
Yeast cells of P. brasiliensis isolate 18 (Pb18) were grown in
Sabouraud Dextrose Broth (BD, MD, USA) at 37uC for 7 days.
Cells were washed and frozen in liquid nitrogen then disrupted by
grinding on a mortar. Total RNA was isolated with Trizol
according to manufacturer’s instruction (Invitrogen, CA, USA).
Complementary DNA was synthesized from 1 mg of total RNA in
the presence of oligo(dT)18 (Fermentas, MD, USA) and Revertaid
M-MuLV(Fermentas, MD, USA).
The P10 nucleotide sequence was obtained using the sense
PCR primer derived from the gp43 [6] 59 nucleotide sequence:
[59-AAT AAG CTT CAA ACC CTG ATC GCC-39], and the
antisense primer derived from the 39 end of the gp43 gene: [59-
AAT GAA TTC ATT GGC GTA ACG GAT TGC-39]. A
HINDIII site and an EcoRI site were added to the sense and
antisense primers, respectively, for cloning into plasmid pcDNA3
(Invitrogen, CA, USA). PCR reactions (50 ml) were carried out
following the protocol provided by Fermentas, using 100 ng of
cDNA and 100 ng of each primer. The P10 PCR reaction started
with one cycle at 94uC (2 min), followed by 40 cycles at 94uC
(30 sec), 55uC (1 min) and 72uC (1 min), and a final 7-min
extension at 72uC. PCR products were purified using Wisard SV
gel and PCR Clean-UP system (Promega, Brazil) and each PCR
product was digested with the appropriate restriction enzyme
(Fermentas) and cloned into the pcDNA3 by directional insertion
in the HINDIII/EcoRI sites. The resulting plasmid was called
pP10.
Plasmid pORF-mIL-12 was acquired from InvivoGen (CA,
USA). The confirmation of the insert was done using the primers:
sense [59-CGG GTT TGC CGC CAG AAC ACA-39] and
antisense [59-GGC CAC CAG CAT GCC CTT GT-39]. The IL-
12 PCR started with one cycle at 94uC (2 min), followed by 40
cycles at 94uC (1 min), 45uC (1 min) and 72uC (2 min), and a final
7-min extension at 72uC.
Preparation of plasmid DNA
To prepare plasmid DNA for immunization, Escherichia coli
XL1Blue and DH5a cells were transformed by electroporation
using Cellject Duo according to the manufacturer’s directions
(Hybaid, Middx, UK) with the DNA constructs or the vector
plasmid alone and then cultured at 37uC in Luria broth
supplemented with ampicillin (50 mg/ml).
The positive clones were confirmed by automatic sequencing
carried out following the protocol provided by Applied Biosystems
(CA, USA) and analyzed by BioEdit and Blast. The parental
vectors, pcDNA3 and pORF were used as negative controls. DNA
for immunization was purified using the EndoFree Giga Kit
(Qiagen, CA, USA) and was diluted in TE buffer to the final
concentration of 1 mg/ml.
Plasmid gene expression in mammalian cells
For the expression of pORF-mIL-12 in mammalian cells, a
transient-transfection assay was performed using Lipofectin
(Invitrogen) and 1 or 2 mg plasmid transfected into HeLa cells
(26105 cells/well). The cells were grown in RPMI medium
supplemented with 10% fetal calf serum (FCS) (Cultilab, SP,
Brazil). After 24 h incubation, the cells were harvested, and total
RNA was isolated with Trizol for reverse transcription (RT)-PCR.
IL-12 PCR was used as described above. IL-12p70 was detected
(80 ng/ml) by ELISA, in the supernatant of transfected HeLa
cells.
Author Summary
Paracoccidioidomycosis (PCM) is the predominant system-
ic mycosis in Latin America causing half of the total deaths
among systemic fungal infectious diseases in Brazil.
Chemotherapy is the standard treatment, but the long
time required, severe cases of immunosuppression and
frequent relapses indicate that additional methods should
be introduced such as immunotherapy combined with
antifungal drugs. Previously, the protective activity of P10,
a peptide derived from the major diagnostic antigen gp43,
was demonstrated, alone or combined with chemothera-
py. P10 elicited a vigorous IFN-c mediated Th-1 immune
response. Presently, the reduction of fungal load, and even
sterilization, was attempted using a specific DNA vaccine
encoding P10. Plasmid pcDNA3 expression vector with P10
insert was tested as a vaccine in intratracheally infected
BALB/c and B10.A mice. Our results showed that vaccina-
tion with pP10 induced a significant reduction of the
fungal burden in the lung. Co-vaccination of pP10 with a
plasmid encoding mouse IL-12 proved to be even more
effective in the elimination of the fungus with virtual
sterilization in a long term infection and treatment assay
system. The data suggest that immunization with these
plasmids, without the need of an adjuvant, could be used
in the prevention and treatment of PCM in human
patients.
Experimental DNA Vaccine against PCM
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P10 expression from vector pcDNA3, followed by IFN-c
production
DNA immunization was performed by injecting groups of 5 six-
week-old male BALB/c mice intramuscularly in both quadriceps
with three doses of 100 mg of plasmid encoding P10 (pP10), 50 mg
of either pP10 and pcDNA3 vector alone, or 50 mg of the pcDNA3
vector alone, each in 50 ml of TE buffer. A total of three
immunizations were given at weekly intervals in alternating sites
on the left and right hind legs. The mice were euthanized one
week after the last immunization, their spleens were isolated and
single-cell suspensions were prepared by gentle homogenization in
RPMI medium supplemented with 1% FCS. Cells were suspended
and treated with isotonic ammonium chloride to lyse erythrocytes.
The splenocytes were washed by centrifugation, suspended in
RPMI containing 10% FCS, and dispensed into wells on a
microtitering plate (56105 mononuclear cells per well). The
cultures were stimulated with 20 mg/ml of synthetic P10. After 24
and 48-h incubation at 37uC with 5% CO2, supernatants were
collected and IFN-c was assayed by a sandwich enzyme-linked
immunoassay (ELISA) (BD Pharmingen, CA, USA). Splenocytes
from animals immunized with pP10 and stimulated with synthetic
P10 produced 10 and 15 ng/ml IFN-c after 24 and 48 h,
Figure 1. Summary of the treatment protocols used. First protocol: BALB/c mice received 4 weekly injections. Animals were infected and
sacrificed 30 or 60 days later. Second protocol: BALB/c and B10.A mice were infected intratracheally. Mice received 4 weekly vaccine doses and
animals were sacrificed 1 week after the last injection. Third protocol: B10.A mice were infected i.t. and one month after infection, they were
immunized with the DNA vaccine. The animals were sacrificed one month after the last injection, six months after infection.
doi:10.1371/journal.pntd.0001519.g001
Experimental DNA Vaccine against PCM
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respectively. When 50 mg of pcDNA3 was used for immunization,
9 and 11 ng/ml IFN-c was released by splenocytes at the two
examined times.
Ethics statement
This study was carried out as recommended by the Brazilian
college of animal experimentation (COBEA). The protocol has
been approved by the Ethical Committee on Animal Experimen-
tation of University of Sa˜o Paulo (Permit number: 039).
Animals
BALB/c and B10.A mice were bred at the Institute of
Biomedical Science of University of Sa˜o Paulo, Department
of Immunology animal facility under specific-pathogen-free
conditions.
Fungal strain
Yeast cells of the virulent isolate Pb 18 of P. brasiliensis were
maintained by weekly subculturing on Sabouraud Dextrose Agar
and incubation at 37uC. Before experimental infection, 7–10 day-
old cells were inoculated into Sabouraud Dextrose Broth and
incubated at 37uC for 5–7days with rotary shaking. Fungal cells
were washed three times in phosphate-buffered saline pH 7.2
(PBS) and counted in a haemocytometer. The viability of fungal
cells in the inoculum was determined by staining with Janus B
(Merck, Darmstadt, Germany) and was greater than 90%.
Intratracheal infection of BALB/c and B10.A mice
BALB/c and B10.A mice (6- to 8-week-old males) were
inoculated intratracheally (IT) with 50 ml suspension of 36105
Pb18 yeast cells in sterile saline (0.85% NaCl). Mice were
anesthetized i.p. with 200 mL of a solution containing 80 mg/kg
ketamine and 10 mg/kg of xylazine (both from Unia˜o Quı´mica
Farmaceˆutica, Brazil). After approximately 10 min, their necks
were extended to expose the trachea at the thyroid level and cell
suspensions were injected with a 26-gauge needle. The incisions
were sutured with 5-0 silk.
Immunization of mice with plasmid DNA
Three different protocols were used (Fig. 1). Injections of 50 mg
plasmid were given in the quadriceps muscle. First protocol:
Groups of 10 BALB/c mice were injected with PBS (control),
pcDNA3 (50 mg; control), pORF (50 ug; control), plasmid
encoding P10 (pP10, 50 mg), plasmid encoding IL-12 (pIL-12,
50 mg) or with both pP10 and pIL-12 (50 ug each). A total of 4
injections were given weekly on alternating sites, on the left and
right hind legs. One week after the last injection, mice were
infected intratracheally then sacrificed 30 or 60 days later.
Second protocol: BALB/c and B10.A mice (10 mice per group)
were infected intratracheally. One month after infection, the mice
received 4 weekly injections of either PBS (control), pcDNA3
(50 mg; control), pP10 (50 mg), pIL-12 (50 mg) or both pP10 and
pPIL-12 (50 ug each). Mice were sacrificed 1 week after the last
Figure 2. Immunoprophylactic treatment of PCM. Gene immunization was initiated 30 days before fungal challenge. CFUs are from lungs of
BALB/c mice infected intratracheally with 36105 yeast cells and subjected to immunization with vectors containing P10 (pP10) and/or IL-12 (pIL-12)
DNA insert. Control mice were inoculated with PBS or with vectors without insert. Mice were sacrificed 30 (&) and 60 (%) days after infection. Each
bar represents the average counts and standard deviations of CFUs in lungs from 10 animals in each group. Experiments were carried out in triplicate
with similar results. **p#0.0001, comparing vector with and without insert; ## p#0.0001, .comparing untreated and other groups.
doi:10.1371/journal.pntd.0001519.g002
Experimental DNA Vaccine against PCM
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injection. Third protocol: B10.A mice (10 mice per group) were
infected intratracheally. One month after infection, they were
treated with 4 weekly injections followed by a monthly booster for
3 additional months (total of 7 injections). The injections were with
either PBS (control), pcDNA3, pP10, pIL-12 or both pP10 and
pPIL-12. The mice were sacrificed one month after the last
injection, six months after infection.
Fungal burden in organs of infected mice
Mice were sacrificed and the lungs, liver and spleen were
removed. Weighed tissue sections were homogenized and then
washed 3 times with PBS and suspended in 1 ml PBS. Suspensions
(100 ml) were inoculated on brain-heart infusion (BHI) agar medium
supplemented with 4% FCS and 5% spent culture medium of P.
brasiliensis (strain-192), streptomycin/penicillin 10 IU/ml (Cultilab)
and cycloheximide 500 mg/ml (Sigma, MO, USA). Colonies were
counted after 10 days of incubation at 37uC.
Histopathology
Lung sections from sacrificed mice were fixed in 10% buffered
formalin for 24 h and embedded in paraffin. Four-micra sections
were stained with haematoxylin-eosin (HE) or silver nitrate
(Gomori) and examined microscopically (Optiphot-2; Nikon,
Tokyo, Japan).
Cytokine detection
Sections of excised lungs were homogenized in 2 ml of PBS in
the presence of protease inhibitors: benzamidine HCl (4 mM),
EDTA disodium salt (1 mM), N-ethylmaleimide (1 mM) and
Pepstatin (1.5 mM) (Sigma, St Louis, MO). The supernatants were
assayed for IL-4, IL-10, IL-12, and IFN-c using ELISA kits (BD
OpTeia, San Diego, CA). The detection limits of the assays were
as follows: 7.8 pg/ml for IL-4, 31.3 pg/ml for IFN-c and IL-10,
62.5 pg/ml for IL-12, as previously determined by the manufac-
turer.
Statistical analysis
Statistical analyses were performed using GraphPad Prism5
software. The results are expressed as means and standard
deviations (SD). The nonparametric Kruskall-Wallis honestly
significant difference test was used. p values are shown in the
Figure legends.
Figure 3. Therapeutic treatment of PCM. Gene immunization started 30 days after infection. CFUs are from lungs of BALB/c (%) and B10.A(&)
mice infected intratracheally with 36105 yeast cells and subjected to immunization with vectors containing P10 (pP10) or IL-12 (pIL-12) DNA inserts.
Control mice were inoculated with PBS or with vectors without insert. Mice were sacrificed 60 days after infection. Each bar represents the average
counts and standard deviations of CFU in lungs from 10 animals in each group. Experiments were performed three times and similar results were
achieved. *p#0.05, **p#0.005, comparing vector with and without insert; ## p#0.005, comparing untreated and other groups.
doi:10.1371/journal.pntd.0001519.g003
Experimental DNA Vaccine against PCM
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Results
Colony-forming units (CFU) in mice immunized prior to
infection (prophylactic immunization). First protocol
To explore the effects of the plasmid with the P10 insert (pP10)
with or without the murine IL-12 gene insert (pIL-12), BALB/c
mice were immunized and then infected intratracheally with
virulent P. brasiliensis Pb 18. Animals were sacrificed after 30 or 60
days, and the fungal burden in the lungs, spleens and livers was
determined. The number of lung CFU per gram of tissue was
significantly reduced in animals immunized with pP10 and/or
pIL-12 compared to controls at both time intervals (Fig. 2).
Notably, we observed that the empty plasmids (pcDNA3 and
pORF) also induced a significant reduction in CFU relative to
mice that received PBS alone, which is presumably a result of
dendritic cell activation through Toll-like receptor 9 binding of
plasmid unmethylated CpG motifs. Immunostimulation by DNA
from P. brasiliensis also attributed to CpG motifs showed protective
effects in susceptible mice [21,22]. Nevertheless, the fungal load
measured in CFUs in mice receiving pP10 and/or pIL-12 was
significantly lower than that in mice treated with control pcDNA3
and pORF. Livers and spleens from all animals had no detectable
fungal cells.
Organ CFUs in mice immunized 1-month after infection
(therapeutic immunization). Second protocol
The therapeutic protocol attempts to reproduce the clinical
reality of patients presenting to medical attention after developing
symptomatic PCM. We studied two mouse strains with different
susceptibilities to PCM, BALB/c (susceptible) and B10.A (highly
susceptible) [23]. The data showed that immunization with pP10
and/or pIL-12 was therapeutic in mice infected with P. brasiliensis
for 1 month prior to receiving plasmid immunizations (Fig. 3).
CFU reductions were significant in infected mice receiving pP10
and/or pIL-12 compared to mice injected with PBS or pcDNA3.
In contrast to the first protocol, injection of pcDNA3 after
installing PCM was not sufficient to reduce the fungal burden. The
most significant reduction in the lung CFUs from B10.A mice was
achieved when pP10 and pIL-12 were combined. The CFUs from
the livers and spleens were barely detectable in all groups.
Organ CFUs in a long-term infection model of B10.A mice
submitted to gene immunization. Third protocol
This protocol allowed us to analyze the efficacy of therapeutic
plasmid treatment during long-term infection (six months) of the
highly susceptible mouse strain, B10.A. Treatment of mice with
PCM using pP10 and/or pIL-12 significantly reduced lung CFUs
(Fig. 4). However, the impact of pIL-12 alone was not as dramatic
as either pP10 alone or pP10 with pIL-12. Notably, treatment with
the combination of pP10 and pIL-12 virtually eradicated the
infection in all organs examined.
Lung histopathology
The lungs of control animals in each experimental protocol
group showed intense inflammation and large numbers of yeast
cells, whereas mice receiving pP10 with or without pIL-12 had
significantly reduced inflammation, and lower or undetectable
fungal cells. Analysis of the lungs of animals from the third
protocol (6 months infection) that received control plasmids
revealed dense infiltration of inflammatory cells, mainly of
macrophages, lymphocytes and epithelioid cells, and numerous
fungal cells (Fig. 5A). Around the foci of epithelioid granulomas,
giant cells were observed. In contrast, there were large areas of
normal lung architecture in pP10-immunized mice and a global
reduction in the number of granulomas with few yeast cells
(Fig. 5B). Treatment with pIL-12 resulted in histological findings
that were more similar to controls than to pP10-immunized mice
(Fig. 5C). Importantly, the lungs of mice treated with the
Figure 4. Long term therapeutic treatment of experimental PCM. Gene immunization started 30 days after infection and mice were sacrificed
6 months after infection. CFUs were counted in lungs of B10.A mice infected intratracheally with 36105 yeast cells and immunized with vectors
containing the insert encoding P10 (pP10) or IL-12 (pIL-12). Control mice were inoculated with PBS or with vector without insert. Each bar represents
the average counts and standard deviations of CFU in lungs from 5 to 10 animals in each group. Experiments were carried out in triplicate, with
similar results. ** p#0.001, comparing vector with and without insert; ##p#0.001, comparing untreated and other groups.
doi:10.1371/journal.pntd.0001519.g004
Experimental DNA Vaccine against PCM
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combination of pP10 and pIL-12 were mostly histologically
normal and no yeast cells were identified (Fig. 5D).
Cytokine assays
Previous studies with BALB/c mice have established that P10
elicits a protective Th-1 immune response [11]. BALB/c and
B10.A mice have different genetic backgrounds that strongly
influence their response to infection by P. brasiliensis. Their
different susceptibility to fungal infection depends in part on their
capacity to produce pro-inflammatory cytokines, which are often
reduced in B10.A relative to BALB/c. IL-4, IL-10, IL-12 and IFN-
c were measured in the lungs of infected B10.A mice and BALB/c.
In mice subjected to the second protocol, BALB/c mice responded
to pcDNA3 and pP10 gene immunization with significant increase
in IFN-c in the lung homogenate compared to untreated or
pcDNA3 treated animals (data not shown). In contrast, B10.A
mice produced significantly less IFN-c after immunization with
pP10 and pcDNA3 in comparison to treatment with pcDNA3
gene alone, which suggests that the increase in IFN-c in both of
these groups relative to untreated mice could be due to dendritic
cell activation by plasmid CpGs. The cytokine production in the
group of animals submitted to the third protocol, in which B10.A
mice treated with pP10 with or without pIL-12 had undetectable
yeasts in the lung tissue, is shown in Table 1. After 6 months post-
infection, cytokine analyses in these mice showed a persistent IFN-
c production regulated by an IL-10-rich immune response, which
is compatible with a protective therapeutic effect in B10.A mice.
Discussion
A vaccine against P. brasiliensis using plasmid DNA was first
tested in 2000 [24,25]. BALB/c mice were immunized with a
Table 1. Cytokines in lung homogenates of B10.A mice
infected i.t. with P. brasiliensis Pb 18 yeasts and submitted to
gene immunization for 5 months.
Cytokines pg/ml IL-10 IFN-c
Untreated 12.1864.61 4.7161.75
pcDNA3 10.3866.53 4.7362.45
pP10+pcDNA3 18.7166.10 7.6462.46
pP10+pIL-12 12.0062.06 7.3161.37
Mice were sacrificed 1 month after the last dose.
doi:10.1371/journal.pntd.0001519.t001
Figure 5. Histopathology of lungs from intratracheally infected B10.A mice. Animals were infected with P. brasiliensis for one month,
treated with or without vectors carrying P10 or IL-12 DNA inserts according to protocol 3, and sacrificed 6 months after the initial infection. Infected
mice treated with (A) control pcDNA3, (B) pP10, (C) pIL-12 DNA, and (D) P10 and IL-12 DNA. Gomori staining; original magnification, 406.
doi:10.1371/journal.pntd.0001519.g005
Experimental DNA Vaccine against PCM
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mammalian expression vector carrying the full gene of the gp43
under the control of CMV promoter with Freund’s adjuvant
resulting in the induction of both B and T cell-mediated immune
responses characterized by a mixed Th-1/Th-2 long-lasting
cellular immune response, chiefly modulated by IFN-c. This
immunization method was protective when performed in mice
prior to challenge with virulent P. brasiliensis. When tested for
immunoprotection, P10 in Freund’s adjuvant was also active in the
murine model of PCM, eliciting an IFN-c-dependent Th-1
immune response [11,20]. The combined treatment of P10-
vaccine in Freund’s adjuvant and chemotherapy, either an azole,
amphotericin B, or sulfamethoxazole, stimulated a protective Th-1
response, rich in IL-12 and IFN-c, that was therapeutically
beneficial if initiated 2 or 30 days after intratracheal infection [19].
The combined treatment was also effective in anergic animals
challenged with the fungus [20].
Presently we used a DNA vaccine encoding P10 with or without
a plasmid encoding IL-12 that is administered without adjuvant.
We found that the pP10 vaccine, either given prior to or 1 month
after intratracheal infection, induced a significant reduction in the
fungal burden in the lungs of mice. Co-vaccination with murine
pIL-12 significantly enhanced vaccine effectiveness, particularly in
a long- term infection model in B10.A mice. The combined DNA
vaccine (Protocol 3) achieved virtual sterilization after 6 months
with histologically normal lungs and undetectable fungal burden.
Full protection was mediated by IFN-c production and the pro-
inflammatory effect of pP10 and pIL-12 was regulated by IL-10 in
these susceptible mice.
The mechanism of fungal killing by gene immunization is not
solely mediated by cytokines since the empty plasmid pcDNA3 is a
strong stimulator of the immune system. However, a significant
protection is only achieved with pP10 or pP10+pIL-12 adminis-
tration. P10 is not protective in IFN-c-KO mice [12], indicating
that this cytokine is essential for fungal killing through macrophage
activation. T-CD4+ lymphocytes recognizing P10 and other cells
induced by fungal infection are the main producers of IFN-c. A
role for a simultaneous induction of protective antibodies against
fungal antigens [26] is also recognized.
IL-12 administration has been previously studied in experimental
PCM [27]. Our current results show that IL-12 protected mice
against disseminated infection. In the long term infection protocol,
pIL-12 alone was only partially effective in the protection of infected
mice, but the cytokine facilitated the elimination of P. brasiliensis
when combined with pP10. This is a very encouraging result and
strongly suggests that a pP10-based vaccine associated with pIL-12
could be used as a powerful adjuvant to chemotherapy.
Despite the effectiveness of chemotherapy, fatalities from
invasive or systemic fungal diseases are not uncommon. Vaccines
against fungal diseases are gaining increasing attention, owing to
their capacity to effectively modulate the immune response
(reviewed in [28]. The frequent occurrence of clinical relapses
and sequellae, such as pulmonary fibrosis, following antifungal
chemotherapy suggest that immunoprotective vaccines could also
reduce the incidence of these complications [29].
In addition to our work with P10, there have been other notable
attempts to develop vaccine strategies for the treatment of PCM.
They included a cDNA encoding the antigenic protein rPb27 [30],
the recombinant heat shock protein 60 emulsified in adjuvant [31],
radioattenuated P. brasiliensis yeast cells [32] and Mycobacterium
leprae DNAhsp65 plasmid in infected BALB/c mice [33]. Braga
et al. [34] immunized BALB/c mice either with recombinant
purified flagellins (FliC) genetically fused with P10 or with the
synthetic P10 peptide mixed with purified FliC. A prevailing Th1-
type immune response was obtained that reduced P. brasiliensis
growth and lung damage in infected mice.
From a practical standpoint, the broad use of antifungal
vaccines is not realistic when considering the perspective of a large
number of infected people relative to the number of individuals
who develop the disease. Mycoses caused by dimorphic fungi, such
as PCM, coccidioidomycosis, histoplasmosis and blastomycosis,
have low incidence as a deep-seated disease. Certain fungal
diseases such as cryptococcosis, aspergillosis and candidiasis
typically occur in immunocompromised hosts. Hence, targeted
prophylactic vaccination may be a more practical approach to
control disease. In the case of PCM, immunization of those at
highest risk, such as farmers in highly endemic regions would be
reasonable. However, we have also demonstrated that the pP10/
pIL-12 combination is highly efficacious after PCM has developed.
Therefore, immunization could be most useful in combination
with standard therapy in PCM patients in order to enhance
treatment efficacy, reduce treatment duration and, perhaps,
prevent relapses.
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